Page last updated: 2024-11-04

vorinostat and Epithelial Neoplasms

vorinostat has been researched along with Epithelial Neoplasms in 2 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"Approximately 50% of serous epithelial ovarian cancers (EOC) contain molecular defects in homologous recombination (HR) DNA repair pathways."1.40Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. ( Khabele, D; Konstantinopoulos, PA; Saskowski, J; Wass, E; Wilson, AJ, 2014)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, S1
Zhao, Y1
Gou, WF1
Zhao, S1
Takano, Y1
Zheng, HC1
Konstantinopoulos, PA1
Wilson, AJ1
Saskowski, J1
Wass, E1
Khabele, D1

Other Studies

2 other studies available for vorinostat and Epithelial Neoplasms

ArticleYear
The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cel

2013
Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Gynecologic oncology, 2014, Volume: 133, Issue:3

    Topics: Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation;

2014